Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.

Journal of clinical gastroenterology - 1 Jul 2008

Floreani Annarosa, Baldo Vincenzo, Rizzotto Erik Rosa, Carderi Isabella, Baldovin Tatjana, Minola Eliseo

Abstract excerpt

BACKGROUND: Data on the efficacy of antiviral therapy in patients with HCV-related compensated cirrhosis are generally drawn from analyzing subgroups in larger trials. AIMS: (1) To analyze the safety and efficacy of combination therapy in naive patients with HCV-related cirrhosis; (2) to evaluate the factors influencing the sustained virologic response (SVR) in cirrhotic patients by comparison with a group of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 18285717
DOI: 10.1097/MCG.0b013e318046ea75

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.PMID 18285717Read ↗

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.Semantic proximity Read ↗

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.Semantic proximity Read ↗

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.Semantic proximity Read ↗

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].Semantic proximity Read ↗

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver DiseaseSemantic proximity Read ↗

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.Semantic proximity Read ↗

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.